Your browser doesn't support javascript.
loading
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
De Ruysscher, Dirk; Dingemans, Anne-Marie C; Praag, John; Belderbos, Jose; Tissing-Tan, Caroline; Herder, Judith; Haitjema, Tjeerd; Ubbels, Fred; Lagerwaard, Frank; El Sharouni, Sherif Y; Stigt, Jos A; Smit, Egbert; van Tinteren, Harm; van der Noort, Vincent; Groen, Harry J M.
Affiliation
  • De Ruysscher D; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Dingemans AC; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Praag J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Belderbos J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Tissing-Tan C; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Herder J; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Haitjema T; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Ubbels F; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Lagerwaard F; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • El Sharouni SY; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Stigt JA; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Smit E; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • van Tinteren H; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • van der Noort V; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
  • Groen HJM; Dirk De Ruysscher and Anne-Marie C. Dingemans, Maastricht University Medical Center; GROW Research Institute, Maastricht; John Praag, Erasmus University Medical Center, Rotterdam; Jose Belderbos, Egbert Smit, Harm van Tinteren, and Vincent van der Noort, Netherlands Cancer Institute; Frank Lagerwaar
J Clin Oncol ; 36(23): 2366-2377, 2018 08 10.
Article in En | MEDLINE | ID: mdl-29787357
ABSTRACT
Purpose The purpose of the current study was to investigate whether prophylactic cranial irradiation (PCI) reduces the incidence of symptomatic brain metastases in patients with stage III non-small-cell lung cancer (NSCLC) treated with curative intention. Patients and Methods Patients with stage III NSCLC-staged with a contrast-enhanced brain computed tomography or magnetic resonance imaging-were randomly assigned to either observation or PCI after concurrent/sequential chemoradiotherapy with or without surgery. The primary end point-development of symptomatic brain metastases at 24 months-was defined as one or a combination of key symptoms that suggest brain metastases-signs of increased intracranial pressure, headache, nausea and vomiting, cognitive or affective disturbances, seizures, and focal neurologic symptoms-and magnetic resonance imaging or computed tomography demonstrating the existence of brain metastasis. Adverse effects, survival, quality of life, quality-adjusted survival, and health care costs were secondary end points. Results Between 2009 and 2015, 175 patients were randomly assigned 87 received PCI and 88 underwent observation only. Median follow-up was 48.5 months (95% CI, 39 to 54 months). Six (7.0%) of 86 patients in the PCI group and 24 (27.2%) of 88 patients in the control group had symptomatic brain metastases ( P = .001). PCI significantly increased the time to develop symptomatic brain metastases (hazard ratio, 0.23; [95% CI, 0.09 to 0.56]; P = .0012). Median time to develop brain metastases was not reached in either arm. Overall survival was not significantly different between both arms. Grade 1 and 2 memory impairment (26 of 86 v seven of 88 patients) and cognitive disturbance (16 of 86 v three of 88 patients) were significantly increased in the PCI arm. Quality of life was only decreased 3 months post-PCI and was similar to the observation arm thereafter. Conclusion PCI significantly decreased the proportion of patients who developed symptomatic brain metastases with an increase of low-grade toxicity.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Cranial Irradiation / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials Aspects: Patient_preference Limits: Female / Humans / Male Language: En Journal: J Clin Oncol Year: 2018 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Cranial Irradiation / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Clinical_trials Aspects: Patient_preference Limits: Female / Humans / Male Language: En Journal: J Clin Oncol Year: 2018 Document type: Article